One of the main arguments made for bodyoids is that they could provide spare human organs. There’s a huge shortage of organs ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

Top FDA official Peter Marks was forced to resign as the director of the Center for Biologics Evaluation and Research.

AbbVie, Danaher, Thermo Fisher Scientific, Cognizant Technology Solutions, Vertex Pharmaceuticals, Alnylam Pharmaceuticals, ...

the Novo Nordisk-partnered biotech has struck a deal with its founder Flagship Pioneering that could see it file for bankruptcy and lay off up to 17 people. Story Jan. 29 - Cargo Therapeutics ...

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

Fidelity Select Biotechnology Portfolio earns an Average ... Its attractive expense ratio, paired with the fund’s People, Process, and Parent Pillars, suggests that this share class should ...

AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early ... spinal cord in around five in 100,000 people. The molecule already has orphan status ...